A Look At Innoviva (INVA) Valuation After Shelf Registration For Potential US$208 Million Stock Offering

Simply Wall St.

May 05

AdvertisementInnoviva’s Shelf Registration and What It Could Mean for Shareholders Innoviva (INVA) has filed a shelf registration to potentially offer up to US$207.99 million of common stock, covering...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2633949083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633949083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633949083?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-05 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633949083","market":"us","top_or_hot":-1,"title":"A Look At Innoviva (INVA) Valuation After Shelf Registration For Potential US$208 Million Stock Offering","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementInnoviva’s Shelf Registration and What It Could Mean for Shareholders Innoviva (INVA) has filed a shelf registration to potentially offer up to US$207.99 million of common stock, covering...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innoviva-inva-valuation-after-shelf-registration-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Innoviva (INVA) Valuation After Shelf Registration For Potential US$208 Million Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Innoviva (INVA) Valuation After Shelf Registration For Potential US$208 Million Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-05 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innoviva-inva-valuation-after-shelf-registration-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementInnoviva’s Shelf Registration and What It Could Mean for Shareholders Innoviva (INVA) has filed a shelf registration to potentially offer up to US$207.99 million of common stock, covering...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innoviva-inva-valuation-after-shelf-registration-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innoviva-inva-valuation-after-shelf-registration-f","article_id":"2633949083","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innoviva-inva-valuation-after-shelf-registration-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633949083","pubTimestamp":1777991414,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Innoviva’s Shelf Registration and What It Could Mean for Shareholders\nInnoviva (INVA) has filed a shelf registration to potentially offer up to US$207.99 million of common stock, covering 9,000,000 shares in an ESOP related transaction that could influence future valuation.\nSee our latest analysis for Innoviva.\nAgainst the backdrop of this shelf registration and a fresh equity incentive plan, Innoviva’s recent share price return has been mixed in the very short term, but supported by stronger...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药","INVA":"Innoviva, Inc."},"translate_title":"Innoviva(INVA)潜在2.08亿美元股票发行登记后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"INVA":1.5},"content_text":"AdvertisementInnoviva’s Shelf Registration and What It Could Mean for Shareholders Innoviva (INVA) has filed a shelf registration to potentially offer up to US$207.99 million of common stock, covering 9,000,000 shares in an ESOP related transaction that could influence future valuation. See our latest analysis for Innoviva. Against the backdrop of this shelf registration and a fresh equity incentive plan, Innoviva’s recent share price return has been mixed in the very short term, but supported by stronger momentum over longer periods, with a 90 day share price return of 9.48% and a 1 year total shareholder return of 22.68%. If this kind of corporate activity has you looking beyond a single stock, it can be a good time to see which other companies are drawing attention in related areas through 33 healthcare AI stocks With Innoviva trading at US$22.99 against an analyst price target of US$33.20 and an indicated intrinsic discount of 57.81%, you have to ask: is the stock undervalued, or is the market already pricing in future growth? Price-to-Earnings of 6.3x: Is It Justified? On a P/E of 6.3x, Innoviva looks inexpensive compared to many peers, especially when set against the last close price of $22.99 and its recent performance. The P/E ratio compares the current share price to earnings per share and is a common way to see how much investors are paying for each dollar of profit. For a profitable biopharmaceutical company with a reported net income of $271.17 million on revenue of $411.33 million, the P/E can give a quick sense of how the market is weighing current earnings against future expectations. Here, Innoviva’s P/E of 6.3x sits well below the US Pharmaceuticals industry average of 17x and the peer average of 20.1x. This gap suggests the market is assigning a much lower earnings multiple than many comparable stocks. It is also below the estimated fair P/E of 10.9x, which is a level the valuation work suggests the multiple could move toward if conditions align. Explore the SWS fair ratio for Innoviva Result: Price-to-Earnings of 6.3x (UNDERVALUED) However, investors still need to weigh risks such as potential dilution from the shelf registration and the impact of slower net income growth of a 3% annual decline. Find out about the key risks to this Innoviva narrative. Another Way to Look at Value The SWS DCF model values Innoviva’s future cash flows at $54.49 per share, compared with the current price of $22.99. That gap points to a potentially undervalued stock on this method. It also raises a key question: are the underlying cash flow assumptions realistic for you? Look into how the SWS DCF model arrives at its fair value. INVA Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With these mixed signals on valuation, risks, and potential rewards, it makes sense to examine the data closely and decide what it means for you. To see both sides laid out clearly, check the 3 key rewards and 3 important warning signs Looking for more investment ideas? If Innoviva has sharpened your focus, do not stop here. Broaden your watchlist with stocks that fit clear themes so potential opportunities do not slip past.  Target value opportunities by scanning 48 high quality undervalued stocks that combine appealing prices with solid fundamentals. Prioritize resilience by reviewing 70 resilient stocks with low risk scores that score well on stability and financial strength. Spot early potential by checking the screener containing 25 high quality undiscovered gems before the broader market starts paying attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}